HK1221910A1 - 用於癌症治療的免疫刺激性 衍生多肽 - Google Patents

用於癌症治療的免疫刺激性 衍生多肽

Info

Publication number
HK1221910A1
HK1221910A1 HK16110146.4A HK16110146A HK1221910A1 HK 1221910 A1 HK1221910 A1 HK 1221910A1 HK 16110146 A HK16110146 A HK 16110146A HK 1221910 A1 HK1221910 A1 HK 1221910A1
Authority
HK
Hong Kong
Prior art keywords
hiv tat
immunostimulatory
cancer treatment
derivative polypeptides
polypeptides
Prior art date
Application number
HK16110146.4A
Other languages
English (en)
Inventor
Joshua Goldberg
Colin Bier
Original Assignee
Pin Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pin Pharma Inc filed Critical Pin Pharma Inc
Publication of HK1221910A1 publication Critical patent/HK1221910A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16071—Demonstrated in vivo effect
HK16110146.4A 2013-10-04 2016-08-25 用於癌症治療的免疫刺激性 衍生多肽 HK1221910A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361887166P 2013-10-04 2013-10-04
PCT/US2014/059035 WO2015051245A1 (en) 2013-10-04 2014-10-03 Immunostimulatory hiv tat derivative polypeptides for use in cancer treatment

Publications (1)

Publication Number Publication Date
HK1221910A1 true HK1221910A1 (zh) 2017-06-16

Family

ID=51904222

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16110146.4A HK1221910A1 (zh) 2013-10-04 2016-08-25 用於癌症治療的免疫刺激性 衍生多肽

Country Status (11)

Country Link
US (3) US9663556B2 (zh)
EP (1) EP3052127A1 (zh)
JP (1) JP2016533352A (zh)
CN (1) CN105705164A (zh)
AU (1) AU2014329393B2 (zh)
CA (1) CA2926221A1 (zh)
HK (1) HK1221910A1 (zh)
IL (1) IL244867B (zh)
RU (1) RU2695653C2 (zh)
WO (1) WO2015051245A1 (zh)
ZA (1) ZA201602196B (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6607784B2 (ja) * 2012-12-06 2019-11-20 ピーアイエヌ ファーマ インコーポレイテッド 免疫抑制性Ｔａｔ誘導体ポリペプチドを用いた炎症、自己免疫及び神経変性疾患の治療
RU2695653C2 (ru) * 2013-10-04 2019-07-25 Пин Фарма, Инк. Иммуностимулирующие полипептидные производные тат вич для применения в лечении рака

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2631355B1 (fr) 1988-05-13 1990-09-07 Doris Engineering Dispositif de protection pour ouvrages en mer et procede pour la mise en oeuvre dudit dispositif
US5670617A (en) 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
US6316003B1 (en) 1989-12-21 2001-11-13 Whitehead Institute For Biomedical Research Tat-derived transport polypeptides
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
JPH05506031A (ja) 1990-03-30 1993-09-02 スミスクライン・ビーチャム・コーポレイション 免疫不全ウイルス感染に伴う疾病の抑制
WO1991018454A1 (en) 1990-05-18 1991-11-28 Centre National De La Recherche Scientifique Compositions capable of blocking cytotoxicity of viral regulatory proteins and neurotoxic symptoms associated with retroviral infection
US5219990A (en) 1991-01-28 1993-06-15 Biogen, Inc. Papillomavirus e2 trans-activation repressors
CZ288048B6 (cs) 1991-07-25 2001-04-11 Idec Pharmaceuticals Corporation Farmaceutická kompozice k indukci cytotoxické odpovědi T-lymfocytů
US5350835A (en) 1991-11-05 1994-09-27 Board Of Regents, University Of Texas Cellular nucleic acid binding protein and uses thereof in regulating gene expression and in the treatment of aids
WO1994015634A1 (en) 1992-12-30 1994-07-21 Matthias Rath Tat and rev oligopeptides in hiv treatment
FR2700169B1 (fr) 1993-01-04 1995-03-24 Transgene Sa Nouveaux variants trans-dominants TAT du virus de l'immunodéficience humaine.
US5981258A (en) 1993-12-13 1999-11-09 Transgene S.A. Composition of trans-dominant variants of viral proteins for obtaining an antiviral effect
US6228369B1 (en) 1993-12-13 2001-05-08 Transgene S.A. Composition of trans-dominant variants of viral proteins for obtaining an anti-viral effect
US5817308A (en) 1994-02-14 1998-10-06 University Of Rochester Tolerogenic fusion proteins of immunoglobulins and methods for inducing and maintaining tolerance
DE69535500D1 (de) 1994-02-14 2007-07-05 Macfarlane Burnet Ct For Medic Nicht pathogene stämme des hiv-1
DE4405810A1 (de) 1994-02-23 1995-08-24 Behringwerke Ag Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung
EP0767678A1 (en) 1994-05-23 1997-04-16 Gideon Goldstein Compositions of transactivating proteins of human immunodeficiency virus
DE69535905D1 (de) 1994-07-15 2009-02-26 Coley Pharm Group Inc Immunomodulatorische Oligonukleotide
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
PL322143A1 (en) 1995-03-08 1998-01-05 Neovacs Non-topxic immunogenes originating frommretroviral regulator protein, antibodies as such, method of preparing them and pharmaceutic compositions containing them
US6846493B2 (en) 1995-09-01 2005-01-25 Millenium Biologix Inc. Synthetic biomaterial compound of calcium phosphate phases particularly adapted for supporting bone cell activity
US5976786A (en) 1995-12-29 1999-11-02 National Jewish Medical And Research Center Screening methods for the identification of compounds that modulate apoptosis in immunodeficiency virus infected cells
US6200575B1 (en) 1996-03-07 2001-03-13 Neovacs Non-toxic immunogens derived from a retroviral regulatory protein antibodies preparation process and pharmaceutical compositions comprising them
EP0834569A1 (en) 1996-10-03 1998-04-08 Roche Diagnostics GmbH Thermostable DNA polymerase from carboxydothermus hydrogenoformans
US6686333B1 (en) 1996-10-04 2004-02-03 The United States Of America As Represented By The Department Of Health And Human Resources Inhibition of HIV replication using soluble Tat peptide analogs
US6024965A (en) 1996-10-18 2000-02-15 Erasums University Rotterdam Induction of REV and TAT specific cytotoxic T-cells for prevention and treatment of human immunodeficiency virus (HIV) infection
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
WO1998043669A1 (en) 1997-04-03 1998-10-08 Thomas Jefferson University Chimeric viral proteins
US20010007659A1 (en) 1997-04-17 2001-07-12 The University Of California Use of lentiviral vectors for antigen presentation in dendritic cells
US6339068B1 (en) 1997-05-20 2002-01-15 University Of Iowa Research Foundation Vectors and methods for immunization or therapeutic protocols
ES2210761T3 (es) 1997-05-21 2004-07-01 The Board Of Trustees Of The Leland Stanford Junior University Composicion y procedimiento para mejorar el transporte a traves de las membranas biologicas.
US5891994A (en) * 1997-07-11 1999-04-06 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
AU6492498A (en) 1997-08-05 1999-03-01 Stressgen Biotechnologies Corporation Immune responses against hpv antigens elicited by compositions comprising an HPV antigen and a stress protein or an expression vector capable of expression of these proteins
GB9720585D0 (en) 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
IT1297090B1 (it) 1997-12-01 1999-08-03 Barbara Ensoli Tat di hiv-1 o suoi derivati, da soli od in combinazione, a scopo vaccinale, profilattico e terapeutico, contro l'aids i tumori e le
FR2773156B1 (fr) 1997-12-26 2000-03-31 Biovacs Inc Nouveaux immunogenes anti-retroviraux (toxoides), nouveaux procedes de preparation et application a la prevention et au traitement du sida
FR2781158B1 (fr) 1998-07-15 2002-12-13 Vacs Internat Nouvelles proteines modifiees immunogenes non immunosuppressives, leur procede de preparation et leurs applications
US6497880B1 (en) 1998-12-08 2002-12-24 Stressgen Biotechnologies Corporation Heat shock genes and proteins from Neisseria meningitidis, Candida glabrata and Aspergillus fumigatus
WO2000059935A1 (en) 1999-04-05 2000-10-12 Mayo Foundation For Medical Education And Research Anti-apoptotic fusion polypeptide
FR2792206B1 (fr) 1999-04-13 2006-08-04 Centre Nat Rech Scient Vaccin anti-vih-1 comprenant tout ou partie de la proteine tat de vih-1
WO2000078334A1 (en) 1999-06-17 2000-12-28 University Of Maryland Biotechnology Institute Chimeric chemokine-antigen polypeptides and uses therefor
AU4082300A (en) 1999-06-21 2001-01-09 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Hiv tat peptides and multiple peptide conjugate system
CA2376992A1 (en) 1999-06-29 2001-01-04 Smithkline Beecham Biologicals S.A. Use of cpg as an adjuvant for hiv vaccine
US6495347B1 (en) 1999-07-08 2002-12-17 Stressgen Biotechnologies Corporation Induction of a Th1-like response in vitro
US8323928B2 (en) 1999-08-12 2012-12-04 Pin Pharma, Inc. Vaccines and immunotherapeutics derived from the human immunodeficiency virus (HIV) transactivator of transcription protein for the treatment and prevention of HIV disease
WO2001012220A1 (en) 1999-08-12 2001-02-22 Cohen David I Non-immunosuppressant hiv tat
US20050226890A1 (en) 1999-08-12 2005-10-13 Cohen David I Tat-based vaccine compositions and methods of making and using same
MXPA02001857A (es) 1999-08-24 2003-07-14 Cellgate Inc Composiciones y metodos para incrementar la entrega de drogas a traves y dentro de tejidos epiteliales.
AT408721B (de) 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
FR2802426B1 (fr) 1999-12-15 2004-04-02 Neovacs Utilisation de proteines immunogenes immunosuppressives et/ou angiogeniques rendues inactives, pour la production d'iga secretoires
AT409085B (de) 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
MXPA02007413A (es) 2000-01-31 2004-07-30 Smithkline Beecham Biolog Vacuna para la inmunizacion profilactica o terapeutica contra el vih.
US20030198941A1 (en) 2000-04-12 2003-10-23 Watkins David I. Method for making an HIV vaccine
US6399067B1 (en) 2000-04-28 2002-06-04 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
AUPQ776100A0 (en) 2000-05-26 2000-06-15 Australian National University, The Synthetic molecules and uses therefor
US6544780B1 (en) 2000-06-02 2003-04-08 Genphar, Inc. Adenovirus vector with multiple expression cassettes
PT1296711E (pt) 2000-06-26 2006-08-31 Stressgen Biotechnologies Corp E7 de vph para o tratamento do virus do papiloma humano
US20080044435A1 (en) 2004-03-16 2008-02-21 Cohen David I Tat-Based Tolerogen Compositions and Methods of Making and Using Same
US20070248618A1 (en) 2004-03-16 2007-10-25 Cohen David I Tat-Based vaccine Compositions and Methods of Making and Using Same
WO2006033665A1 (en) 2004-03-16 2006-03-30 Inist Inc. Tat-based vaccine compositions and methods of making and using same
EP1315816B1 (en) 2000-09-08 2010-12-29 University Of Maryland Biotechnology Institute Genetically engineered co-expression dna vaccines, construction methods and uses thereof
FR2814958B1 (fr) 2000-10-06 2003-03-07 Aventis Pasteur Composition vaccinale
US20040034209A1 (en) 2001-01-26 2004-02-19 David Ho Vaccination of hiv infected persons following highly active antiretrovial therapy
EP1279404A1 (en) 2001-07-26 2003-01-29 Istituto Superiore di Sanità Use of HIV-1 tat, fragments or derivatives thereof, to target or to activate antigen-presenting cells, to deliver cargo molecules for vaccination or to treat other diseases
CA2469487A1 (en) 2001-12-11 2003-07-03 Aventis Pasteur Mutated hiv tat
IL164354A0 (en) 2002-04-04 2005-12-18 Coley Pharm Gmbh Immunostimulatory g,u-containing oligoribonucleotides
US20040009949A1 (en) 2002-06-05 2004-01-15 Coley Pharmaceutical Group, Inc. Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory CpG nucleic acids
US6786160B1 (en) 2003-05-02 2004-09-07 Zeftek, Inc. Beam isolator
EP1638993A4 (en) 2003-06-10 2007-05-09 Univ Melbourne IMMUNOMODULATING COMPOSITIONS, APPLICATIONS THEREOF AND METHOD FOR THE PRODUCTION THEREOF
US20050203041A1 (en) 2003-09-23 2005-09-15 Mourich Dan V. Antisense compound and method for selectively killing activated T cells
FR2868318B1 (fr) 2004-04-01 2012-11-16 Commissariat Energie Atomique Antigene tat stabilise et ses applications pour la vaccination anti-vih
BRPI1009215B1 (pt) * 2009-03-23 2019-10-29 Nanirx Inc composição farmacêutica compreendendo uma sequência de aminoácidos modificada da proteína trans-ativadora de transcrição (tat) do vírus da imunodeficiência humana (hiv) e uso de um polipeptídeo derivado de tat para tratar câncer
WO2011128720A1 (en) * 2010-04-14 2011-10-20 Mymetics Corporation Trans-activator of transcription protein
US9856320B2 (en) * 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
JP6607784B2 (ja) * 2012-12-06 2019-11-20 ピーアイエヌ ファーマ インコーポレイテッド 免疫抑制性Ｔａｔ誘導体ポリペプチドを用いた炎症、自己免疫及び神経変性疾患の治療
RU2695653C2 (ru) * 2013-10-04 2019-07-25 Пин Фарма, Инк. Иммуностимулирующие полипептидные производные тат вич для применения в лечении рака

Also Published As

Publication number Publication date
IL244867A0 (en) 2016-05-31
RU2695653C2 (ru) 2019-07-25
AU2014329393B2 (en) 2020-04-30
ZA201602196B (en) 2017-11-29
US20150098960A1 (en) 2015-04-09
IL244867B (en) 2020-01-30
US9663556B2 (en) 2017-05-30
EP3052127A1 (en) 2016-08-10
RU2016112538A3 (zh) 2018-08-23
AU2014329393A1 (en) 2016-04-28
CN105705164A (zh) 2016-06-22
US20190030117A1 (en) 2019-01-31
WO2015051245A1 (en) 2015-04-09
JP2016533352A (ja) 2016-10-27
US20170274040A1 (en) 2017-09-28
US10159707B2 (en) 2018-12-25
RU2016112538A (ru) 2017-11-13
CA2926221A1 (en) 2015-04-09

Similar Documents

Publication Publication Date Title
IL245558B (en) Cytotoxic peptides and their conjugates
IL251630A0 (en) Combined therapy for use in cancer treatment
ZA201505735B (en) Cancer drug and uses
GB201322725D0 (en) Cancer therapy
HK1220900A1 (zh) 癌症的治療
SG11201507847UA (en) Cancer therapy
IL253549B (en) Antibody-urease conjugates for therapeutic purposes
HK1222548A1 (zh) 治療惡性腫瘤的藥物組合
PL2777671T3 (pl) Stół dla pacjenta
GB201318686D0 (en) Pharmaceutical preparations
IL242584B (en) An immunogenic preparation for use in treatment
IL255560A (en) Macrophinocytosis in cancer
EP2961412A4 (en) CANCER THERAPY
GB201301721D0 (en) Pharmaceutical Preparations
HK1221910A1 (zh) 用於癌症治療的免疫刺激性 衍生多肽
GB201307348D0 (en) Garment for therapeutic treatment
EP3013332A4 (en) Cancer treatment
ZA201508585B (en) Immunogenic composition for use in therapy
EP3104863C0 (en) SALICYLATE FOR USE IN THE TREATMENT OF CANCER
GB201300546D0 (en) Cancer Treatment
GB201416493D0 (en) Polypeptides for use in therapy
GB201317213D0 (en) Cancer Therapy
GB201305073D0 (en) Therapeutic means
GB201321531D0 (en) Treatment for cancers
AU2013105V (en) DCGL Dianella caerulea